Related Experiment Video
Updated: Aug 4, 2025
06:13
Stepwise Dosing Protocol for Increased Throughput in Label-Free Impedance-Based GPCR Assays
Published on: February 21, 2020
6.6K
Optimal dosing of gliclazide-A model-based approach
Sabiha R Mim1, Haneen Hussein1, Samira Vidadi1
1Pharmacometric Research Group, Department of Pharmacy, Uppsala University, Uppsala, Sweden.
Basic & Clinical Pharmacology & Toxicology
|March 31, 2023
Summary
Optimizing gliclazide dosing for type 2 diabetes is crucial. Pharmacometric models suggest increasing the modified-release (MR) dose to 270mg can improve glycemic control without increasing hypoglycemia risk compared to immediate-release (IR) formulations.
Area of Science:
- Pharmacometrics
- Pharmacokinetics
- Pharmacodynamics
- Diabetes Mellitus
Background:
- Gliclazide, a type 2 diabetes treatment, was approved before modern model-based drug development.
- Current dosing recommendations may not be optimized for efficacy and safety.
Purpose of the Study:
- To investigate various gliclazide dosing regimens using pharmacometric models.
- To characterize the dose-response relationship for immediate-release (IR) and modified-release (MR) formulations.
Main Methods:
- Literature search for 21 gliclazide pharmacokinetic (PK) studies.
- Development of PK models for IR and MR gliclazide formulations.
- Integration of PK/PD data using an integrated glucose-insulin model to assess concentration-response.
Main Results:
- Simulations indicated a maximum efficacy of 44% of patients achieving HbA1c <7%.
- The recommended IR dose (320mg) is appropriate, with no further efficacy gain at higher doses.
- The MR formulation dose can potentially be increased to 270mg, improving HbA1c <7% achievement without exceeding the hypoglycemia risk of the IR dose.
Conclusions:
- The current IR gliclazide dose is considered appropriate.
- Increasing the MR gliclazide dose to 270mg may enhance glycemic control in type 2 diabetes patients.
- Model-based analysis provides a framework for optimizing gliclazide dosing strategies.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
248
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
248
01:06Oral Hypoglycemic Agents: Glinides
197
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
197
01:16Insulin: Dosing Regimen and Adverse Effects
220
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
220
01:23Dipeptidyl Peptidase 4 Inhibitors
220
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
220
01:24Glucagon-like Receptor Agonists
374
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
374
01:14Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches
192
Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
192